Case report
Open access
Sep 2026
Early deep response to cilta-cel as 2nd CAR T-Cell therapy after CELMoD-based bridging for advanced multiple myeloma
Abstract Chimeric antigen receptor (CAR) T-cell therapy has emerged as an innovative and highly effective treatment option for patients with relapsed/refractory multiple myeloma (RRMM). This effect is based on redirecting modified T-cells towards plasma cells expressing target antigens, specifically B cell maturation a...
Henrik Niklas, A. Bold, S. Völkl et al.
· Annals of Hematology · 0 citations